Source

2011/869/EU: Commission Decision of 20 December 2011 amending Decision 2002/364/EC on common technical specifications for in vitro diagnostic medical devices (notified under document C(2011) 9398) Text with EEA relevance

Decision 2002/364/EC · Decision · 4 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Open ↗

The Annex to Decision 2002/364/EC is amended in accordance with the Annex to this Decision.

Article 2

Open ↗

This Decision shall apply from 1st of July 2012. However, Member States shall allow manufacturers to apply the requirements set out in the Annex before the date set out in the first paragraph of this Article.

Article 3

Open ↗

This Decision is addressed to the Member States.

Supplementary provisions

ANNEXSupplementary provisions

Open ↗

ANNEX 1. The following section is added at the end of Section 3 of the Annex to Decision 2002/364/EC: ‘3.7. CTS for Variant Creutzfeldt-Jakob disease (vCJD) assays for blood screening CTS for Variant Creutzfeldt-Jakob disease (vCJD) assays for blood screening are set out in Table 11’ 2. The following table is added at the end of the Annex to Decision 2002/364/EC: ‘ Table 11 Variant Creutzfeldt-Jakob disease (vCJD) assays for blood screening Material Number of specimens Acceptance Criteria Analytical sensitivity vCJD brain spikes in human plasma (WHO reference number NHBY0/0003) 24 replicates of each of three dilutions of the material WHO number NHBY0/0003 (1×10 4 , 1×10 5 , 1×10 6 ) 23 of the 24 replicates detected at 1×10 4 vCJD spleen spikes in human plasma (10 % spleen homogenate — NIBSC reference number NHSY0/0009) 24 replicates of each of three dilutions of the material NIBSC number NHSY0/0009 (1×10, 1×10 2 , 1×10 3 ) 23 of the 24 replicates detected at 1×10 Diagnostic sensitivity A) Specimen from appropriate animal models As many specimen as reasonably possible and available, and at least 10 specimens 90 % B) Specimen from humans with known clinical vCJD As many specimen as reasonably possible and available, and at least 10 specimens 90 % Only in case where 10 specimens are not available: — the number of specimens tested shall be comprised between 6 and 9 — all available specimens shall be tested no more than one false negative result Analytical specificity Potentially cross-reacting blood-specimens 100 Diagnostic specificity Normal human plasma samples from area of low BSE exposure 5 000 At least 99,5 %’

Other acts of the same type

2011/885/EU: Council Decision of 14 November 2011 on the signing, on behalf of the European Union, and the provisional application of the Protocol agreed between the European Union and the Republic of Guinea-Bissau setting out fishing opportunities and the financial contribution provided for in the Fisheries Partnership Agreement between the two parties currently in force Commission Implementing Decision of 9 November 2011 on a financial contribution from the Union towards emergency measures to combat foot-and-mouth disease in Bulgaria in 2011 (notified under document C(2011) 7993)2011/737/,Euratom: Commission Decision of 9 November 2011 amending its Rules of Procedure 2011/731/: Council Decision of 8 November 2011 on the conclusion, on behalf of the European Union, of the 2006 International Tropical Timber Agreement 2011/732/: Council Decision of 8 November 2011 on the conclusion of the Agreement between the European Union and the Republic of Cape Verde on certain aspects of air services 2011/733/: Council Decision of 8 November 2011 on the conclusion of an Agreement on the participation of the Republic of Bulgaria and Romania in the European Economic Area and four related agreements 2011/791/EU: Council Decision of 8 November 2011 amending Decision 2011/734/EU addressed to Greece with a view to reinforcing and deepening fiscal surveillance and giving notice to Greece to take measures for the deficit reduction judged necessary to remedy the situation of excessive deficit 2011/818/EU: Council Decision of 8 November 2011 on the conclusion of the Agreement in the form of an Exchange of Letters between the European Union and the Kingdom of Norway concerning additional trade preferences in agricultural products reached on the basis of Article 19 of the Agreement on the European Economic Area Commission Implementing Decision of 7 November 2011 establishing the financial contribution by the Union to the expenditure incurred in the context of the emergency measures taken to combat avian influenza in Denmark in 2010 (notified under document C(2011) 7850)2011/728/: Decision of the European Central Bank of 31 October 2011 amending Decision ECB/2010/15 concerning the administration of EFSF loans to Member States whose currency is the euro, and amending Decision ECB/2010/31 concerning the opening of accounts for the processing of payments in connection with EFSF loans to Member States whose currency is the euro (ECB/2011/16)2012/63/EU: Commission Decision of 31 October 2011 — State aid SA. 30931 (C/11) — Romania — Aid scheme for the development of air transport infrastructure (notified under document C(2011) 7863) Text with EEA relevance Commission Implementing Decision of 28 October 2011 amending Implementing Decision 2011/402/EU on emergency measures applicable to fenugreek seeds and certain seeds and beans imported from Egypt (notified under document C(2011) 7744) Text with EEA relevance

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

What to look at next

Browse all EU Legal ActsEvery instrument by type and year, full text free to read section by sectionEuropean Union legislation EU Legal Acts by type and yearGrouped by instrument type and year of enactment, so you can find others of the same kindBrowse by type and year European Union: what this database coversWhich datasets are here, which official source they come from, and how current they areEuropean Union overview